Publication: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.

Information

PGS Catalog Publication (PGP) ID: PGP000031
PubMed ID: 26291059
doi: 10.1038/bjc.2015.289

Publication Date: Aug. 20, 2015

Journal: Br J Cancer

Authors: Pashayan N, Pharoah PD, Schleutker J, Talala K, Tammela TLj, Määttänen L, Harrington P, Tyrer J, Eeles R, Duffy SW, Auvinen A.

PGS Associated with PGP000031

PGS Developed By This Study

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.
PGS Performance Metric (PPM) ID Evaluated Score PGS Catalog Sample Set (PSS) ID Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in PGS Model PGS Performance: Other Relevant Information
PPM000104 PGS000044 (PrCa66) PSS000068 Pashayan N et al. (2015) Reported Trait: Elevated serum prostate-specific antigen (PSA) levels OR (per 1-point increase in PRS): 1.23 [1.1 - 1.37] cancer stage, Gleason score

Evaluated Samples

PGS Catalog Sample Set (PSS) ID Detailed Phenotype Description (e.g. ICD/SNOMED codes used to identify cases) Sample Numbers Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. 8,796 individuals
[ 2,148 cases, 6,648 controls]
100.00 %% Male samples
European ProtecT
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. 5,059 individuals
[ 4,099 cases, 960 controls]
100.00 %% Male samples
European SEARCH
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml. 3,157 individuals
[ 3,157 cases, 0 controls]
100.00 %% Male samples
European UKGPCS